Results 201 to 210 of about 56,538 (251)

Factors associated with the progression of disability (EDSS) among MS patients. [PDF]

eNeurologicalSci
Arteaga-Noriega A, Zapata-Berruecos J, Gutiérrez-Vargas J, Garcia JC, Rojas-Gualdron D, Restrepo-Botero M.   +5 more
europepmc   +1 more source

Hidden Challenges: A Cross-Sectional Study on Prevalence and Determinants of Sexual Dysfunction in Men and Women with Multiple Sclerosis. [PDF]

Medicina (Kaunas)
Latella D, Giambò FM, La Rosa G, Bonanno L, Calabrò RS.   +4 more
europepmc   +1 more source

Acceptability of Telehealth as the Default Modality for Multiple Sclerosis Care in Switzerland: Cross-Sectional Study.

JMIR Mhealth Uhealth
Ekongefeyin SNN, Daniore P, Nittas V, Iaquinto S, Vallejo-Yagüe E, Kamm CP, Calabrese P, Baum C, Gobbi C, Zecca C, Chan A, Puhan M, von Wyl V.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Relapsing-remitting tumefactive multiple sclerosis

Multiple Sclerosis Journal, 2005
Tumefactive multiple sclerosis (MS) is a rare form of demyelinating disease. The natural course of the disease has been characterized as presenting with a mass-like demyelinating lesion converting to typical relapsing-remitting disease with future exacerbations.
Stephen M, Selkirk, Jiong, Shi
openaire   +2 more sources

Therapeutic inertia in relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders, 2021
Therapeutic inertia (TI) is defined as a failure to initiate or intensify treatments despite evidence of disease activity. Its prevalence and determining factors in Relapsing-Remitting Multiple Sclerosis (RRMS) patients in Portugal are not known. The main objective of this work was to ascertain the prevalence of TI in RRMS and its determining factors ...
Rita, Rodrigues, Raquel, Rocha, Gonçalo, Bonifácio, Daniela, Ferro, Francisco, Sabença, Ana Isabel, Gonçalves, Filipe, Correia, Joaquim, Pinheiro, José Leal, Loureiro, Rui Pedro, Guerreiro, José, Vale, Maria José, Sá, Andreia, Costa   +12 more
openaire   +2 more sources

Fingolimod for relapsing-remitting multiple sclerosis

Cochrane Database of Systematic Reviews, 2016
Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the frequency of exacerbations and to delay disability worsening. Issues on its safety and efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.To assess the safety ...
Loredana, La Mantia, Irene, Tramacere, Belal, Firwana, Ilaria, Pacchetti, Roberto, Palumbo, Graziella, Filippini   +5 more
openaire   +2 more sources

[Relapsing-Remitting Multiple Sclerosis].

Brain and nerve = Shinkei kenkyu no shinpo, 2021
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system. There are neither diagnostic tests nor markers for MS. Other causes must be excluded thoroughly before an MS diagnosis is considered definitive. The relapsing-remitting type is a major clinical course in MS. Most disease-modifying drugs (DMDs)
Masaaki, Niino, Yusei, Miyazaki
openaire   +1 more source